ArticleCell biochemistry and biophysics2025
Antitumor Potential of the Pterocarpanoquinone-Quinone LQB-472 in Prostate Cancer Cells.
Article in Cell biochemistry and biophysics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate cancer is among the most common in the world. Since it is a very resistant type of cancer, the search for new therapeutic alternatives becomes crucial. Aiming to research new molecules to treat prostate cancer, a set of five derivatives of the previously proven antiprostatic LQB-118 molecules were synthesized, and their in vitro antitumor action was screened by MTT and Trypan Blue dye exclusion assays. The cell cycle and cell death by apoptosis were analyzed using flow cytometry. The derivatives LQB-471, LQB-472, LQB-473, LQB-474, and LQB-475 cytotoxicities were analyzed in hormone-sensitive (LNCaP) and resistant (PC3) prostate tumor cell lines, as well as in the Vero non-tumor cell line. LQB-471, LQB-472, and LQB-474 induced cytotoxicity in both tumor cell lines, with LQB-472 being the most active, acting in a time and concentration-dependent manner in both prostate tumor lineages. In 72 h of incubation, LQB-472 showed IC50 of 1.79 µM and 0.92 µM (MTT) for LNCaP and PC3 tumor cells, respectively, and 5,7 higher for the Vero cells (IC50 = 7.14 µM), indicating preferential cytotoxicity to tumor cells. LQB-472 treatment also showed an increase in cell death through apoptosis. LQB-472 is known as pterocarpanoquinone-quinone because it has two para-naphthoquinone (1,4-naphthoquinone) groups, where an additional 1,4-benzoquinone ring was inserted between rings C and D of the LQB-118 structure. In conclusion, the structure-activity relationship analysis of the studied molecules indicates that the binding site and the position of the methoxy group in the molecule are crucial for the antitumor effect. The duplicity of the para-naphthoquinone group, observed in the LQB-472, was directly associated with the five times amplified effect observed concerning LQB-118 (4.6 µM). The results obtained with LQB-472 are quite promising and encourage the continuation of its pre-clinical studies due to its potential use in the treatment of prostate cancer.
Indexed as
Identifiers
40759859What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.